Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Clinical Trial
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
Webcast and Conference Call To be Held Monday November 28, 2022, 8:30 am ETNEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE)...
PCI Biotech interim Q3 2022 report
Oslo (Norway), 23 November 2022 – PCI Biotech (OSE: PCIB), today announces its interim Q3 2022 results. Please find enclosed...
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Key Points: Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3 trial MSB-GVHD001Overall survival at...
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L These...
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
Lexington Facility uniQure's commercial manufacturing facility in Lexington, MA Manufacturing State-of-the-art global commercial manufacturing at uniQure~ Historic approval provides a...
DBV Technologies to Participate in Upcoming Investor Conference
Montrouge, France, November 22, 2022 DBV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345...
First Wave BioPharma, Inc. Announces Closing of Private Placement
BOCA RATON, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”),...
CNS Summit Releases Annual CNS Summit Innovation Index
BOCA RATON, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Released at the CNS Summit in Boca Raton, FL, the CNS...
Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery
Carlsbad, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for avoidance...
Todos Medical to Attend World Antiviral Congress
New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB:...
CytoDyn to Host R&D Update on Wednesday, December 7, 2022
VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...
IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
LAWRENCEVILLE, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr....
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on...
Outlook Therapeutics® to Present at the BTIG Ophthalmology Day
ISELIN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and...
Microbot Medical’s Novel LIBERTY® Robotic System Continues to be Validated with Latest U.S. Design Patent Allowance
Advanced Features of Remote Controller Specifically Developed to Deliver an Enhanced User Experience During Endovascular ProceduresHINGHAM, Mass., Nov. 18, 2022...
Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer
Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries...
TrueBinding Announces Results of TB006 Phase 1b/2 Placebo Controlled Proof-of-Concept Trial Showing Improvement on the Primary Cognition and Function Endpoint in Patients with Mild to Severe Alzheimer’s Disease
Top line data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients,...
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended as an early intervention to slow disease progression in patients...